Humacyte, Inc.

8-K · tm2617224d1_8k.htm iXBRL

0001818382

 2026-06-10
 2026-06-10

 0001818382

 us-gaap:CommonStockMember

 2026-06-10
 2026-06-10

 0001818382

 HUMA:RedeemableWarrantsEachWholeWarrantExercisableForOneOfCommonAtExercisePriceOf11.50Member

 2026-06-10
 2026-06-10

 iso4217:USD

 xbrli:shares

 iso4217:USD

 xbrli:shares

  

  

  

 UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C. 20549

  

  

  

 FORM 8-K

  

 CURRENT REPORT

 Pursuant to Section 13 or 15(d) of

 the Securities Exchange
Act of 1934

  

 Date of Report (Date of earliest event reported):
 June 10, 2026

  

  

  

 Humacyte, Inc.

 (Exact name of registrant as specified in its charter)

  

  

  

 Delaware
  
 001-39532
  
 85-1763759

 (State or other jurisdiction of

incorporation or organization)
  
 (Commission File Number)
  
 (I.R.S. Employer

Identification Number)

  

 2525 East North Carolina Highway 54

 Durham , NC

  
 27713

 (Address of principal executive offices)
  
 (Zip code)

  

 ( 919 ) 313-9633

 (Registrant’s telephone number, including
area code)

  

 Not Applicable

 (Former name or former address, if changed since
last report)

  

 Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  

 ¨
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 ¨
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 ¨
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 ¨
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

  

 Securities registered pursuant to Section 12(b) of the Act:

  

 Title of each class
  
 Trading Symbol(s)
  
 Name of each exchange on which

 registered

 Common
Stock, par value $0.0001 per share
  
 HUMA
  
 The Nasdaq Stock Market LLC

 Redeemable
Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50
  
 HUMAW
  
 The Nasdaq Stock Market LLC

  

 Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  

 Emerging growth company ¨

  

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
 for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

  

  

  

  

  

 Item 8.01. Other Events.

  

 Clinical Update

  

 On June 10, 2026, Humacyte, Inc. (the “Company”) issued
a press release announcing the presentation of results from its Phase 3 clinical trial (V012) of the acellular tissue engineered vessel
(ATEV) in arteriovenous access for female patients with end-stage renal disease requiring hemodialysis. A copy of this press release is
filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

  

 Investor Presentation

  

 On June 10, 2026, the Company made available an investor presentation
(the “Investor Presentation”), which the Company expects to use in connection with investor calls and/or conferences. A copy
of the Investor Presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

  

 Item 9.01. Financial Statements and Exhibits.

  

 (d) Exhibits.

  

 Exhibit

 Number  

  
 Description

 99.1
  
 Press release, dated June 10, 2026.

 99.2
  
 Humacyte, Inc. Investor
 Presentation June 2026.

 104
  
 Cover Page Interactive Data File (embedded within the
 Inline XBRL document).

  

 1

  

  

 SIGNATURE

  

 Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  
 HUMACYTE,
 INC.

  
  
  

 Date: June 10 ,
 2026
 By:
  /s/
 Dale A. Sander

  
  
 Name:
 Dale A. Sander

  
  
 Title:
 Chief Financial Officer,
 Chief Corporate Development Officer and Treasurer

  

  

 2